ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01

|   Science & Medicine

 EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune response of gamma9 delta2 T cells

ImCheck Therapeutics announced today that the first patient in the U.S. has been dosed at the Yale University Cancer Center in New Haven, Connecticut, as part of the Company’s ongoing EVICTION clinical trial evaluating ICT01 as monotherapy in patients with solid and hematologic malignancies, also in combination with anti-PD-1 inhibitors. The trial, initiated in March 2020, is enrolling patients at clinical sites across Europe and now the U.S., with additional U.S. clinical trial sites to include Moffitt Cancer Center, Tampa, Florida, and the University of Washington/Seattle Cancer Care Alliance.

“Current immunotherapies are proving to be beneficial for patients with some cancers, but we need new approaches and treatments to extend these advances to more patients,” commented Dr. Patricia LoRusso, Associate Center Director for Innovative Medicine at the Yale University Cancer Center, and Investigator in the EVICTION trial. “I believe the gamma9 delta2 T cell activation seen to date with ICT01 has great potential and we are excited to be the first U.S. clinical center to enroll for EVICTION.”

“Expanding the EVICTION trial into the U.S. achieves a key milestone in our international clinical development strategy and follows the recent oral presentation of patient data demonstrating  ICT01’s activation of the anti-tumor immune responses of gamma9 delta2 T cells at the AACR Annual Meeting 2021,” said Pierre d'Epenoux, Chief Executive Officer at ImCheck Therapeutics. “With three leading U.S. cancer centers participating in our EVICTION study, we continue to build our presence in the U.S. and raise awareness for our first-in-class candidate. On behalf of the ImCheck team, I would like to thank the trial investigators and their teams in the U.S. as well as in Europe for their tireless efforts that support ICT01’s progress.”